BioNTech’s Oncology Data Wows, but the Stock Won’t Budge: A $1 Billion Buyback Meets Investor Skepticism

The numbers from Chicago were impressive. On May 30, BioNTech and Bristol Myers Squibb unveiled interim Phase 2 results for Pumitamig in previously untreated advanced non-small cell lung cancer — a 100% disease control rate, high objective response rates across all subtypes and PD-L1 levels, and a manageable safety profile. A separate study for Gotistobart in platinum-resistant ovarian cancer showed durable anti-tumor effects and clinically meaningful survival data as a chemo-free option. The market’s response? Barely a flicker. The stock closed at €74.05 on Monday, roughly 10% below where it started the year and more than 30% off its 52-week high of €105.80 set in January. The relative strength index sat at 34.6, brushing against oversold territory.

That disconnect between clinical progress and share price stems from a straightforward financial reality. BioNTech reported first-quarter 2026 revenue of €118.1 million, down 35% year-on-year, and a net loss that swelled 28% to €531.9 million. The company is burning cash on research while its Covid vaccine franchise shrinks. For the full year, management guides for revenue between €2.0 billion and €2.3 billion — but research and development spending is pegged at €2.2 billion to €2.5 billion. The arithmetic is plain: BioNTech is outspending its top line on the bet that oncology will eventually fill the gap. So far, not a single euro of commercial oncology revenue has materialised.

In an effort to support the stock and signal confidence, BioNTech launched a buyback program on June 8, 2026, authorising up to $1 billion in American Depositary Share repurchases through May 2027. The move comes alongside a deep restructuring. The company plans to shutter production sites in Idar-Oberstein, Marburg and Singapore by the end of 2027, with roughly 1,860 jobs at stake. The goal is annual savings of about €500 million from 2029 onward. The strategic pivot away from Covid and toward oncology is unambiguous — but it remains a work in progress.

The market is pricing in that uncertainty. At €74.70, the stock trades nearly 30% below its January high and a mere 8.3% above its 52-week low of €68.35. The 50-day moving average of €81.02 sits nearly 9% above the current share price and now acts as overhead resistance rather than support. The RSI on the primary article’s reading was 37.1, also flirting with oversold conditions. Analyst consensus sees roughly 43% upside from current levels, with a average target of €106.37 (or $129.56 per American Depositary Share). But the gap between that target and the actual price suggests the market is demanding proof — not pipeline promise.

Should investors sell immediately? Or is it worth buying BioNTech?

The pipeline itself is broad and deep. BioNTech is running more than 25 Phase 2 and Phase 3 trials, including 13 registrational studies. It plans to launch six more Phase 3 trials in 2026 and expects seven late-stage data readouts. The FDA has granted Fast Track designations to several programmes, including BNT113 for HPV16-positive head and neck cancer and BNT111 for advanced melanoma. The science is on schedule. What’s missing is a commercial inflection point.

Meanwhile, institutional investors are slowly accumulating. BNP Paribas, Bank of America and Millennium Management have added to their positions, and smaller funds have entered as new buyers. Institutions now hold roughly 15.5% of outstanding shares. But the buying has not been enough to lift the stock, partly because structural risks cloud the horizon. Proposed cuts in German healthcare spending could squeeze the pricing power BioNTech will need when its first oncology products reach the market — adding political risk to an already high clinical-risk profile.

On the Covid front, the FDA has recommended a monovalent JN.1-lineage XFG composition for autumn 2026, and BioNTech is preparing its seasonal vaccine accordingly. That keeps the legacy franchise alive but does little to alter the fundamental math. The next major catalyst is the second-quarter earnings report, due in a few weeks. Until then, the stock remains trapped between technical support and a wall of skepticism that clinical milestones alone have yet to breach.